51 studies found for:    MK-2206
Show Display Options
Rank Status Study
1 Completed A Phase I Study of MK2206 in Combination With Standard Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors (2206-003 AM5)
Condition: Locally Advanced, Metastatic Solid Tumors
Interventions: Drug: MK-2206 combined with carboplatin + paclitaxel;   Drug: MK-2206 combined with docetaxel;   Drug: MK-2206 combined with erlotinib
2 Active, not recruiting MK2206 and Anastrozole or Fulvestrant and Anastrozole in Treating Postmenopausal Women With Metastatic Breast Cancer
Conditions: Estrogen Receptor-positive Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: Akt inhibitor MK2206;   Drug: anastrozole;   Drug: fulvestrant;   Other: laboratory biomarker analysis
3 Completed A Study of MK2206 in Locally Advanced or Metastatic Solid Tumors (2206-007)
Condition: Solid Tumors
Interventions: Drug: MK2206 every other day;   Drug: MK2206 once weekly
4 Completed Dose Escalation Study With MK2206 in Patients With Locally Advanced or Metastatic Solid Tumors (2206-002)
Conditions: Locally Advanced Tumors;   Metastatic Solid Tumors;   Cancer;   Neoplasms
Intervention: Drug: MK2206
5 Active, not recruiting Dose Defining Study For MK-2206 Combined With Gefitinib In Non Small Cell Lung Cancer (NSCLC)
Condition: Non Small Cell Lung Cancer
Intervention: Drug: MK2206
6 Recruiting Dinaciclib and Akt Inhibitor MK2206 in Treating Patients With Pancreatic Cancer That Cannot Be Removed By Surgery
Conditions: Acinar Cell Adenocarcinoma of the Pancreas;   Duct Cell Adenocarcinoma of the Pancreas;   Recurrent Pancreatic Cancer;   Stage III Pancreatic Cancer;   Stage IV Pancreatic Cancer
Interventions: Drug: dinaciclib;   Drug: Akt inhibitor MK2206;   Other: pharmacological study;   Other: laboratory biomarker analysis
7 Active, not recruiting A Phase II Study of Akt Inhibitor MK2206 in the Treatment of Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer
Conditions: Ovarian Sarcoma;   Recurrent Fallopian Tube Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Primary Peritoneal Cavity Cancer
Interventions: Drug: Akt inhibitor MK2206;   Other: laboratory biomarker analysis
8 Active, not recruiting Lapatinib Ditosylate and Akt Inhibitor MK2206 in Treating Women With Metastatic Breast Cancer
Conditions: Estrogen Receptor-negative Breast Cancer;   Estrogen Receptor-positive Breast Cancer;   HER2-positive Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Progesterone Receptor-positive Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: Akt inhibitor MK2206;   Drug: lapatinib ditosylate;   Other: laboratory biomarker analysis;   Other: pharmacogenomic studies;   Other: pharmacological study
9 Active, not recruiting MK2206 and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Metastatic Breast Cancer
Conditions: Recurrent Breast Cancer;   Stage IV Breast Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: Akt inhibitor MK2206;   Drug: paclitaxel;   Other: pharmacological study;   Other: laboratory biomarker analysis
10 Active, not recruiting Akt Inhibitor MK2206 in Combination With Lapatinib Ditosylate in Patients With Advanced or Metastatic Solid Tumors or Breast Cancer
Conditions: HER2-positive Breast Cancer;   Male Breast Cancer;   Recurrent Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: Akt inhibitor MK2206;   Drug: lapatinib ditosylate;   Other: pharmacological study;   Other: laboratory biomarker analysis
11 Active, not recruiting Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
Conditions: Adenocarcinoma of the Gastroesophageal Junction;   Adenocarcinoma of the Stomach;   Recurrent Esophageal Cancer;   Recurrent Gastric Cancer
Intervention: Drug: Akt inhibitor MK2206
12 Completed A Study of MK2206 in Combination With Trastuzumab and Lapatinib for the Treatment of HER2+ Solid Tumors (2206-015)
Conditions: Advanced Solid Tumors;   Breast Cancer
Interventions: Drug: MK2206;   Drug: Comparator: MK2206;   Biological: Comparator: trastuzumab;   Drug: Comparator: lapatinib
13 Withdrawn Trial of MK-2206 + Endocrine Treatment in Patients With Hormone Receptor Positive Breast Cancer
Condition: Metastatic Breast Cancer
Interventions: Drug: MK-2206;   Drug: Exemestane;   Drug: Goserelin
14 Completed Study of MK-2206 in Patients With Metastatic Neuroendocrine Tumors (NET)
Conditions: PANCREAS;   Neuroendocrine
Intervention: Drug: MK-2206
15 Recruiting Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer
Conditions: Hormone-resistant Prostate Cancer;   Recurrent Melanoma;   Recurrent Prostate Cancer;   Recurrent Renal Cell Cancer;   Stage IIIA Melanoma;   Stage IIIB Melanoma;   Stage IIIC Melanoma;   Stage IV Melanoma;   Stage IV Prostate Cancer;   Stage IV Renal Cell Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: Akt inhibitor MK2206;   Drug: hydroxychloroquine;   Other: pharmacological study;   Other: laboratory biomarker analysis
16 Active, not recruiting PIK3CA Mutation Stratified Trial of MK-2206 in Recurrent or Advanced Endometrial Cancer
Condition: Endometrial Cancer
Intervention: Drug: MK-2206
17 Terminated Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery
Conditions: Adenocarcinoma of the Gastroesophageal Junction;   HER2-positive Breast Cancer;   Male Breast Cancer;   Recurrent Breast Cancer;   Recurrent Esophageal Cancer;   Recurrent Gastric Cancer;   Stage IIIC Breast Cancer;   Stage IIIC Esophageal Cancer;   Stage IIIC Gastric Cancer;   Stage IV Breast Cancer;   Stage IV Esophageal Cancer;   Stage IV Gastric Cancer
Interventions: Drug: Akt inhibitor MK2206;   Biological: trastuzumab;   Drug: lapatinib ditosylate;   Other: laboratory biomarker analysis
18 Recruiting Akt Inhibitor MK2206, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Conditions: B-cell Chronic Lymphocytic Leukemia;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia
Interventions: Drug: Akt inhibitor MK2206;   Biological: rituximab;   Drug: bendamustine hydrochloride;   Other: laboratory biomarker analysis
19 Withdrawn MK-2206 for Recurrent Malignant Glioma
Condition: Malignant Glioma
Intervention: Drug: MK-2206
20 Active, not recruiting Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
Conditions: Recurrent Adenoid Cystic Carcinoma of the Oral Cavity;   Recurrent Salivary Gland Cancer;   Salivary Gland Adenoid Cystic Carcinoma;   Stage IVA Adenoid Cystic Carcinoma of the Oral Cavity;   Stage IVA Salivary Gland Cancer;   Stage IVB Adenoid Cystic Carcinoma of the Oral Cavity;   Stage IVB Salivary Gland Cancer;   Stage IVC Adenoid Cystic Carcinoma of the Oral Cavity
Interventions: Drug: Akt inhibitor MK2206;   Other: laboratory biomarker analysis

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years